Literature DB >> 23186961

Refractory pituitary granulomatosis with polyangiitis (Wegener's) treated with rituximab.

Jing Hughes1, Garni Barkhoudarian, Pedro Ciarlini, Edward R Laws, Elinor Mody, Silvio E Inzucchi, Whitney W Woodmansee.   

Abstract

OBJECTIVE: Granulomatosis with polyangiitis (GPA), also known as Wegener's granulomatosis, is an autoimmune disease characterized by inflammation of blood vessels most often seen in the upper respiratory tract, lungs, kidneys, and skin. Central nervous system (CNS) involvement of GPA is rare, particularly in the pituitary, and can be difficult to treat.
METHODS: Case report.
RESULTS: We present a 30-year-old woman with pituitary and ocular GPA, whose unusually recalcitrant disease led to the development of pan-hypopituitarism and near-total vision loss. After failing multiple systemic immunosuppressants, she was ultimately treated with the novel immunomodulatory agent rituximab together with pulse corticosteroids, which achieved a gratifying response.
CONCLUSION: Pituitary and optic chiasm involvement is a rare complication of GPA. We believe this case illustrates the complexity of management of pituitary GPA and provides insight into the potential utility of the biologic agent rituximab in this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23186961     DOI: 10.4158/EP12181.CR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  8 in total

Review 1.  Non-compressive disorders of the chiasm.

Authors:  Valerie A Purvin; Aki Kawasaki
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

2.  A diagnostic pitfall in IgG4-related hypophysitis: infiltration of IgG4-positive cells in the pituitary of granulomatosis with polyangiitis.

Authors:  Hironori Bando; Genzo Iguchi; Hidenori Fukuoka; Masaaki Taniguchi; Seiji Kawano; Miki Saitoh; Kenichi Yoshida; Ryusaku Matsumoto; Kentaro Suda; Hitoshi Nishizawa; Michiko Takahashi; Akio Morinobu; Eiji Kohmura; Wataru Ogawa; Yutaka Takahashi
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

3.  Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature.

Authors:  Audrey De Parisot; Xavier Puéchal; Corinne Langrand; Gerald Raverot; Helder Gil; Laurent Perard; Guillaume Le Guenno; Sabine Berthier; Olivier Tschirret; Jean Paul Eschard; Stephane Vinzio; Loïc Guillevin; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

4.  Rare presentation of Wegener's granulomatosis in the pituitary gland: Case report and literature review.

Authors:  Samantha M Baird; Upasna Pratap; Catriona McLean; Candice P Law; Nicholas Maartens
Journal:  Int J Surg Case Rep       Date:  2017-02-20

Review 5.  Pituitary Involvement in Granulomatosis with Polyangiitis: A Retrospective Analysis in a Single Chinese Hospital and a Literature Review.

Authors:  Shixuan Liu; Yan Xu; Naishi Li; Shi Chen; Shangzhu Zhang; Linyi Peng; Wei Bai; Jinglan Wang; Jinming Gao; Xiaofeng Zeng; Juhong Shi; Mengzhao Wang
Journal:  Int J Endocrinol       Date:  2019-11-06       Impact factor: 3.257

Review 6.  Granulomatosis with polyangiitis in a patient with polydipsia, facial nerve paralysis, and severe otologic complaints: a case report and review of the literature.

Authors:  Lukas Koenen; Ulf Elbelt; Heidi Olze; Sören Zappe; Steffen Dommerich
Journal:  J Med Case Rep       Date:  2022-07-28

Review 7.  Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review.

Authors:  James E Peters; Vivek Gupta; Ibtisam T Saeed; Curtis Offiah; Ali S M Jawad
Journal:  BMC Neurol       Date:  2018-05-01       Impact factor: 2.474

Review 8.  Severe ophthalmic manifestation in pituitary-involved granulomatosis with polyangiitis: a case report and literature review.

Authors:  Xia Zhang; Bing Xing; Hui You; Huanwen Wu; Yong Zhong; Jin Ma
Journal:  BMC Ophthalmol       Date:  2018-11-16       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.